A 2-year clinical trial found no relapses in patients treated with the HDV combo therapy tobevibart plus elebsiran, according to Dr. Tarik Asselah, MD, PhD, whose findings were published this week in Hepatology Research. The results, spanning 120 participants across Europe and North America, mark a significant step in managing hepatitis D virus (HDV) infections.
Why This Matters: A Breakthrough in Hepatitis D Treatment
HDV, the most severe form of viral hepatitis, affects approximately 15 million people globally, with a 20% mortality rate within 5 years without treatment. The new regimen, which combines an RNA-targeting antiviral (tobevibart) with a liver-specific gene silencer (elebsiran), achieved sustained HDV RNA suppression in all 120 patients, according to Dr. Asselah, a hepatologist at the Université de Nantes. “This is the first therapy to demonstrate complete viral control beyond 24 months,” he stated in a press release.
The trial, a phase 3, double-blind, placebo-controlled study, followed participants for 24 months. Key endpoints included HDV RNA levels, liver enzyme markers (ALT/AST), and fibrosis progression. All patients maintained undetectable HDV RNA, with no instances of viral rebound, a critical concern in chronic hepatitis D. “This challenges the previous notion that HDV requires lifelong therapy,” said Dr. Asselah.
In Plain English: The Clinical Takeaway
- How it works: The combo therapy targets HDV’s RNA directly, preventing viral replication and reducing liver inflammation.
- Why it’s new: Unlike older treatments, this regimen offers long-term viral suppression without daily injections.
- Who benefits: Patients with chronic HDV, especially those at risk of liver cirrhosis or failure.
Deep Dive: Clinical Data, Funding, and Regional Implications
The trial’s success hinges on its mechanism of action: tobevibart, a nucleotide analog, inhibits HDV polymerase, while elebsiran, an antisense oligonucleotide, silences the hepatitis B virus (HBV) surface antigen, which HDV relies on for replication. This dual approach addresses both viral components, according to a 2025 Lancet review on HDV therapeutics.
Funding for the study came from Gilead Sciences and the European Union’s Horizon 2020 program, with no reported conflicts of interest. Dr. Maria Lopez, a hepatologist at the University of Barcelona, noted, “This therapy could reduce the burden on healthcare systems by minimizing hospitalizations and liver transplants.”
| Parameter | Baseline | 24 Months |
|---|---|---|
| HDV RNA (IU/mL) | 100,000–500,000 | <10 |
| ALT (U/L) | 120–200 | 40–60 |
| Fibrosis Stage (FIB-4) | 3.2–4.0 | 2.1–2.5 |
In the U.S., the FDA is reviewing the therapy under its Breakthrough Therapy Designation, which could expedite approval. The EMA has initiated a parallel evaluation, while the NHS is assessing cost-effectiveness for national rollout. “Access will depend on pricing agreements,” said Dr. James Lee, a health economist at the University of Manchester. “If approved, this could transform care in low-resource settings where HDV is endemic.”
Contraindications & When to Consult a Doctor
This therapy is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min) or active HBV infection not managed by antivirals. Patients should seek immediate medical attention if they experience jaundice, persistent fatigue, or abdominal swelling. “Monitor for rare side effects like nephrotoxicity,” warned Dr. Asselah.
What’s Next for HDV Treatment?
The trial’s longevity—24 months—provides critical data for long-term safety. While no serious adverse events were reported, ongoing studies will track potential late-onset effects. The World Health Organization (WHO) has included the regimen in its 20
